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Abstracts
ness to treatments. Typical outputs from these simula-
tions are patient functional status, life years, quality-ad-
justed life years, and associated costs, all of which can be
appropriately discounted. The output information is pre-
sented in the form of distributions which can be used to
estimate mean or median values and confidence intervals
for the outcomes of interest. These results can be used to
compute cost-effectiveness ratios and other drug value
measures. Monte Carlo disease simulation also allows de-
cision makers to address the question of risk associated
with smaller populations that may not tend to the "aver-
age" results generated by Markov models or simulations
of large populations. In this workshop, we describe how
to create a Monte Carlo simulation model and how dif-
ferent types of uncertainty can be incorporated into the
model. We will briefly compare and contrast Monte
Carlo and Markov simulation techniques. Discussion
topics will be illustrated and motivated by an HIV/AIDS
model of the effect of combination antiretroviral therapy
on viral load and CD4 progression. This workshop
should be beneficial to outcomes researchers and health
care decision makers who need to incorporate uncer-
tainty about the natural history of a disease and the im-
pact of alternative disease management strategies for in-
dividual patients into their drug value analyses.
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DESIGNING COMPUTER MODELS TO CONVEY
COST-EFFECTIVENESS ANALYSES RESULTS
Parente ST, Gardner EN, Mohr P
Project HOPE Center for Health Affairs, Bethesda, MD, USA
Results from economic analyses of the effectiveness of
new therapeutic innovations determine whether a new
product will be reimbursed by a managed care organiza-
tion or government agency. Often, the results of these
economic analyses are presented as formal empirical
analyses in scientific journal articles. With the pace of
medical innovations submitted for approval on a payers
fee schedule or formulary list ever increasing, it is impor-
tant to convey the results of analysis as effectively and ef-
ficiently as possible. In response, interactive computer
models have been developed to present the key findings
of an economic analysis. Ideally, these models allow a po-
tential buyer to customize a scientific analysis to deter-
mine their own reservation price for a new product. The
quality and costs of these software applications vary
greatly. Given the resources expended to develop these
models and time to produce them, it useful to examine
the features of cost-effective "laptop model" design. This
workshop will review an inventory of the features of lap-
top models. Participants will gain an understanding of
the development process and costs for developing these
models from the conceptual development phase to pro-
duction of a stand-alone software application. A checklist
of critical ingredients for software development will be
reviewed with a special focus on role of a multidisci-
plinary development team and the capital resources re-
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quired. A review of the discordance between scientists,
biomedical manufactrures, software applications devel-
opers and potential clients and methods to gain consen-
sus to build the application will be discussed. Examples
from Project HOPE's and other firms' software develop-
ment initiatives will be demonstrated as successful appli-
cations currently in use. Participants with a basic knowl-
edge of computer applications, cost-effectiveness methods,
and systems analysis will likely gain the most from this
workshop.
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Holimon TD, Wurtzbacher JD
University of Tennessee College of Pharmacy, Department of
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USA
Combining the measurement of traditional drug utiliza-
tion and other health care resources can provide a good
measure of performance within a health care plan, but
they have not been extensively developed. Following the
workshop, participants should be able to select medical
conditions in a population that are appropriate for drug
usage performance measures, develop a set of drug-based
performance measures from well-established treatment
guidelines, develop appropriate denominators for the per-
formance measures and monitor the results within and
across health care plans. A template and the criteria de-
velopment process for two drug-based performance sets
(asthma and otitis media) will be presented. The role of
performance measures to evaluate trends and to describe
the consequences of implementing managed care to a tra-
ditional Medicaid program will be discussed. Providers
and insurers of health care who are responsible for qual-
ity of care indicators or the drug and disease evaluation
process will benefit from attending this workshop.
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RECONCILING DECISION MODELS WITH THE
REAL WORLD: THE COST-EFFECTIVENESS OF
ERYTHROPOIETIN FOR ESRD·RELATED ANEMIA
Kauf T, Shih Y
UNC School of Pharmacy, Chapel Hill, NC, USA
The choice of data used in decision modeling of health
care interventions divides analysts into two groups: those
who favor randomized clinical trial (RCT) data and those
who prefer "real world" data. This decision may have se-
rious consequences if the end result is to inform health
care policy. This workshop employs a case study to (1)
show how differences in the reality of clinical practice
and the rigor of RCTs can lead to biases when decision
models use RCT data to evaluate policy issues and (2)
provide a method of updating decision models with
claims/outcomes data to overcome this bias. We highlight
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three specific problems associated with the use of RCT
data which may create misleading results: randomization
and sample selection bias, clinically appropriate compar-
ator groups, and indirect treatment effects. These issues
are illustrated with a decision model analyzing Medi-
care's coverage of erythropoietin (EPO) for patients with
End-Stage Renal Disease (ESRD). We show how logistic
and multiple regression can be used to estimate branch
probabilities and payoffs for each treatment group. The
incorporation of additional data from the United States
Renal Data System into the model enables us to update
probabilities and payoffs when patients are not randomly
assigned to treatment modalities. To highlight the poten-
tial bias that exists when models rely solely on RCT data,
we compare our results to a previous study in which the
authors employed a computerized decision model to esti-
mate the net costs to Medicare of EPO coverage at 1 and
5 years. This exercise will offer policy analysts and others
a method of updating RCT-based decision models to
more accurately reflect clinical practice and predict policy
effects.
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COMPARING COMPUTERIZED OPTIONS IN
PHARMACOECONOMICS: SPREADSHEETS,
DECISION TREES, AND EDUCATIONAL
TOOLS: AN OPEN WORKSHOP FOR
DEMONSTRATING SOFTWARE
McGhan WF
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This session is intended for sharing and comparing com-
puter software applications for research, management,
and practice. Software applications will be demonstrated
for decision analysis, cost effectiveness analysis, multi-
attribute utility computation, and assessing patient utili-
ties. Desktop applications will be discussed. Laptop and
handheld computer software will be demonstrated. Phar-
macoeconomic software allows data to be analyzed from
different perspectives: patient, provider, hospital, man-
aged care, and society. Software models also allow assess-
ment of health care products or services from different
quantitative perspectives: cost of illness, cost minimiza-
tion, cost-benefit, cost-effectiveness, and cost-utility. The
integration of decision analysis and spreadsheets will also
be discussed. Software is utilized to collect information,
analyze data, present findings, or educate managers, pro-
viders and patients. Pros and cons of each analytical and
software approach will be discussed. Participants are en-
couraged to bring their own laptops to demonstrate their
own software or related Internet offerings in an informal




DECISION ANALYSIS: WHAT IS ITS UTILITY FOR
PHARMACOECONOMIC ANALYSIS?
Caro JJ, Migliaccio-Walle K
Caro Research, Boston, MA, USA
Among many techniques available for pharmacoeco-
nomic analysis (PEA), some, such as decision analysis
(DA), have been formally defined, whereas others are still
in the early stages of development and are less well de-
fined. Used for quite some time in the business sector, DA
has been adopted for PEA for its apparent straightfor-
ward nature and ease of use.
METHODS: To evaluate the utility of DA techniques for
PEA, an analysis of treatment for gastroesophageal reflux
disease (GERD) will be presented as an example and the
basic tenets of DA examined.
RESULTS: Although the basic decision tree for the
GERD model appeared straightforward, it became clear
upon implementation just how difficult it is to fit disease
management and progression into such a model. Instead
of the standard two alternative-two outcome textbook
examples, there were six initial choices, three potential
early outcomes, and countless subsequent resulting "next
steps." As with most PEA, it was also necessary to explic-
itly account for time as many model elements depended
on time.
CONCLUSIONS: Among problems with DA are: time is
not explicitly accounted for, the use of dual values (cost,
effectiveness) was not intended, and cost and effective-
ness values must be specified at a terminal node though
they are actually cumulative. Thus, DA is clear only for
simple models - more often it is overly complex, compu-
tationally inefficient, and very difficult to validate. Tech-
niques better suited to PEA will be discussed. Any person
who uses, or is interested in using, PEA in his or her work
will benefit from attending this session.
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ISSUES IN DEVELOPING ECONOMIC MODELS
FOR MANAGED CARE: THE CASE OF
OSTEOPOROSIS PREVENTION
Funk Orsini pi, Mullins CD2, Weiss SR2, Preston KL'
'PAREXEL International, Alexandria, VA, USA; -University of
Maryland, Baltimore, MD, USA
Although efficacy and safety data remain the mainstay of
formulary decisions, the need for economic evaluation of
new pharmaceutical products has become increasingly
important within the managed care environment. For
many new products, insufficient information is generated
from clinical trials to conduct a comprehensive economic
evaluation. Therefore, economic modeling is often the
only feasible option for delivering timely information to
decision makers about a new product's value. Unfortu-
nately, economic models presented to managed care plans
often have limited usefulness because they lack relevance
or applicability to the plan's members or the overall goals
